NCT05660265View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 26, 2023

Primary Completion Date

February 27, 2026

Study Completion Date

February 27, 2026

Conditions
Hematologic DiseasesAnaemia, Sickle Cell
Interventions
DRUG

GSK4172239D

Different strength of GSK4172239D will be administered in different cohorts.

OTHER

Placebo

Matching placebo will be administered.

Trial Locations (8)

27617

WITHDRAWN

GSK Investigational Site, Raleigh

30274

RECRUITING

GSK Investigational Site, Riverdale

30315

RECRUITING

GSK Investigational Site, Atlanta

31904

RECRUITING

GSK Investigational Site, Columbus

33155

RECRUITING

GSK Investigational Site, Miami

33165

RECRUITING

GSK Investigational Site, Miami

33321

RECRUITING

GSK Investigational Site, Tamarac

89113

RECRUITING

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05660265 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years | Biotech Hunter | Biotech Hunter